Onconova Therapeutics, Inc. (NASDAQ:ONTX) clinical-stage biopharmaceutical firm, is reporting third quarter earnings results on Thursday 12th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.03 per share from $ 1.39 million in revenue.
For the full year, analysts predict revenues of $ 2.34 million, while looking forward to loss of $ 0.13 per share.
Previous Quarter Performance
Onconova Therapeutics, Inc. unveiled loss for the second quarter of $ 0.04 per share, from the revenue of $ 0.06 million. The quarterly revenues reduced 97.00 percent compared with the same quarter last year. Street analysts expected Onconova Therapeutics, Inc. to report loss of $ 0.03 per share on revenue of $ 0.17 million for the second quarter. The bottom line results missed street analysts by $ 0.01 or 33.33 percent, at the same time, top line results fell short of analysts by $ 0.11 million or 64.71 percent.
Stock Performance
Shares of Onconova Therapeutics, Inc. traded low $ 0.00 or -1.21 percent on Wednesday, reaching $ 0.27 with volume of 3.35 million shares. Onconova Therapeutics, Inc. has traded high as $ 0.28 and has cracked $ 0.27 on the downward trend
The closing price of $ 0.27, representing a 170.00 % increase from the 52 week low of $ 0.10 and a 82.69 % decrease over the 52 week high of $ 1.56.
The company has a market capital of $ 49.60 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Onconova Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (855) 428-5741 or (210) 229-8823 Outside U.S., when prompted, enter passcode 8687160 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.onconova.com
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.
